• 1. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 4. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines N-alkylpiperazines

Comprehensive Overview of (R)-1-CYCLOHEXYL-3-METHYL-PIPERAZINE (CAS No. 182141-99-7): Properties, Applications, and Industry Insights

(R)-1-CYCLOHEXYL-3-METHYL-PIPERAZINE (CAS No. 182141-99-7) is a chiral piperazine derivative gaining traction in pharmaceutical and chemical research due to its unique stereochemistry and functional versatility. As a cyclohexyl-substituted piperazine, this compound exhibits distinct physicochemical properties, making it valuable for asymmetric synthesis and drug discovery. The (R)-enantiomer specificity of this molecule is particularly noteworthy, as it often influences biological activity and receptor binding affinity in medicinal chemistry applications.

Recent trends in chiral building blocks have propelled interest in compounds like (R)-1-CYCLOHEXYL-3-METHYL-PIPERAZINE. Pharmaceutical researchers frequently search for "CAS 182141-99-7 solubility" or "piperazine derivatives for CNS drugs," reflecting its potential in neurological target development. The compound's lipophilic cyclohexyl moiety enhances membrane permeability—a critical factor addressed in modern drug design queries such as "improving blood-brain barrier penetration."

From a synthetic perspective, 182141-99-7 serves as a privileged scaffold in organocatalysis and ligand design. Its methyl-piperazine core participates in hydrogen bonding interactions, while the chiral center enables stereoselective transformations. Laboratories often investigate "N-alkylation of (R)-1-CYCLOHEXYL-3-METHYL-PIPERAZINE" or "resolution methods for piperazine enantiomers," indicating its role in method development.

The compound's stability profile meets contemporary demands for sustainable chemistry, with researchers examining "green synthesis routes for CAS 182141-99-7." Its crystalline form (often queried as "(R)-1-CYCLOHEXYL-3-METHYL-PIPERAZINE polymorphs") demonstrates good shelf life under standard storage conditions, a practical consideration for industrial scale-up.

Analytical characterization of 182141-99-7 typically involves chiral HPLC methods and spectroscopic techniques, with frequent searches for "NMR data of (R)-1-CYCLOHEXYL-3-METHYL-PIPERAZINE." The compound's high optical purity (>98% ee) makes it particularly useful for structure-activity relationship studies in drug candidate optimization.

Emerging applications include its use as a precursor to bioactive molecules, with patent literature describing derivatives targeting GPCR modulation. This aligns with frequent queries about "piperazine-based kinase inhibitors" and "chiral amines in asymmetric catalysis." The steric hindrance from the cyclohexyl group often features in discussions about "controlling regioselectivity in N-functionalization."

Quality control protocols for (R)-1-CYCLOHEXYL-3-METHYL-PIPERAZINE emphasize residual solvent analysis and enantiomeric excess determination, addressing industry concerns about "pharmaceutical-grade chiral amines." The compound's low hygroscopicity (a searched property as "water content in 182141-99-7") facilitates handling in manufacturing environments.

From a regulatory standpoint, proper documentation of stereochemical identity is crucial, reflected in searches for "chiral certification of CAS 182141-99-7." The compound's non-hazardous classification under standard safety assessments contributes to its adoption in combinatorial chemistry libraries.

Future research directions may explore its metal complexation behavior (as suggested by queries about "piperazine ligands for catalysis") or bioconjugation potential. The growing demand for enantiopure intermediates ensures continued relevance of this structurally constrained amine in cutting-edge chemical development.

• 1038338-37-2(2-(4-methylpiperazin-1-yl)cyclohexan-1-amine)
• 5467-34-5((4aS,8aS)-1,4-dibutyl-2,3,4a,5,6,7,8,8a-octahydroquinoxaline)
• 1187930-87-5((S)-1-Cyclohexyl-3-methylpiperazine)
• 5467-39-0(Quinoxaline,decahydro-1-methyl-, cis-)
• 6335-64-4((4as,8as)-1,4-dipropyl-2,3,4a,5,6,7,8,8a-octahydroquinoxaline)
• 6335-62-2(Quinoxaline,decahydro-1-methyl-, (4aR,8aR)-rel-)
• 6327-21-5(2,4,6-Pyrimidinetriamine,N4-(3,4-dimethylphenyl)-5-ethyl-)
• 67198-33-8(Cyclohexanamine, N-methyl-2-(4-methyl-1-piperazinyl)-, trans-)
• 5467-35-6(1,4-dipropyl-2,3,4a,5,6,7,8,8a-octahydroquinoxaline)
• 6640-42-2(Quinoxalinium,1,1,4,4-tetrabutyldecahydro-, dichloride, trans- (9CI))